Title:
5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2022/114189
Kind Code:
A1
Abstract:
Provided is a compound that exerts an anticancer effect based on the inhibition of CHK1. The present disclosure has been completed based on the finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof has a strong inhibitory effect on CHK1 and thus exhibits an excellent antitumor effect [in the formula: R1, R2, L, V, W and Q are as defined in the description; X, Y, and Z each independently represent CR8 or a nitrogen atom, provided that X, Y, and Z do not represent CR8 at the same time; and R8 is as defined in the description].
More Like This:
Inventors:
KAMIOKA SEIJI (JP)
BAN HITOSHI (JP)
MATSUOKA MAKOTO (JP)
HIROSE WATARU (JP)
SHIMADA NAOAKI (JP)
HAYASHI KENTO (JP)
UMEHARA HIROKI (JP)
BAN HITOSHI (JP)
MATSUOKA MAKOTO (JP)
HIROSE WATARU (JP)
SHIMADA NAOAKI (JP)
HAYASHI KENTO (JP)
UMEHARA HIROKI (JP)
Application Number:
PCT/JP2021/043666
Publication Date:
June 02, 2022
Filing Date:
November 29, 2021
Export Citation:
Assignee:
SUMITOMO PHARMA CO LTD (JP)
International Classes:
C07D403/14; A61K9/08; A61K9/127; A61K31/497; A61K31/5377; A61K45/00; A61K47/10; A61K47/24; A61K47/28; A61K47/32; A61K47/34; A61P35/00; A61P35/02; A61P43/00; C07D413/14
Domestic Patent References:
| WO2010077758A1 | 2010-07-08 | |||
| WO2017132928A1 | 2017-08-10 | |||
| WO2012064548A1 | 2012-05-18 | |||
| WO2021104461A1 | 2021-06-03 | |||
| WO2010077758A1 | 2010-07-08 | |||
| WO2012064548A1 | 2012-05-18 | |||
| WO2017132928A1 | 2017-08-10 |
Foreign References:
| JP2017508787A | 2017-03-30 | |||
| JP2020198648A | 2020-12-10 |
Other References:
"Latest Drug Discovery Chemistry: From Exploratory Research to Development", 15 August 1998, TECHNOMIC CO., LTD. , JP , ISBN: 4-924746-59-2, article C.G.WERMUTH (ED.): "Chapter 13 Transformation of molecules based on equivalent substitution", pages: 235 - 271, XP009536823
DAI YGRANT S, CLIN CANCER RES, vol. 16, no. 2, 2010, pages 376 - 383
BENADA JMACUREK L, BIOMOLECULES, vol. 5, 2015, pages 1912 - 1937
DENT P, EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 28, no. 12, 2019, pages 1095 - 1100
EVANGELISTI G. ET AL., EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 29, no. 8, 2020, pages 779 - 792
THEODORA W. GREENEPETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
CURR OPIN DRUG DISCOV DEVEL., vol. 13, no. 1, January 2010 (2010-01-01), pages 66 - 77
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 1, no. 1, 2005, pages 3 - 13
XENOBIOTICA, vol. 39, no. 2, 2009, pages 99 - 112
DRUG METABOLISM AND DISPOSITION, vol. 39, no. 7, 2011, pages 1247 - 1254
DAI YGRANT S, CLIN CANCER RES, vol. 16, no. 2, 2010, pages 376 - 383
BENADA JMACUREK L, BIOMOLECULES, vol. 5, 2015, pages 1912 - 1937
DENT P, EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 28, no. 12, 2019, pages 1095 - 1100
EVANGELISTI G. ET AL., EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 29, no. 8, 2020, pages 779 - 792
THEODORA W. GREENEPETER G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
CURR OPIN DRUG DISCOV DEVEL., vol. 13, no. 1, January 2010 (2010-01-01), pages 66 - 77
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 1, no. 1, 2005, pages 3 - 13
XENOBIOTICA, vol. 39, no. 2, 2009, pages 99 - 112
DRUG METABOLISM AND DISPOSITION, vol. 39, no. 7, 2011, pages 1247 - 1254
Attorney, Agent or Firm:
YAMAMOTO, Shusaku et al. (JP)
Download PDF: